Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medena AG is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being handled by a distinct examiner and a distinct art unit. MELLER, MICHAEL V is the busiest examiner for the company, overseeing the 1 pending office action. This indicates a singular focus for the company's current prosecution activity at the USPTO.
The data shows that a distinct examiner is managing the entirety of the company's pending workload, which consists of 1 pending office action. MELLER, MICHAEL V's assignment to this matter within the art unit suggests a highly specific technical review process. For practitioners, this profile represents a minimal administrative footprint with no current complexity arising from multiple examiners or diverse art units. The concentration of the portfolio into a single pending action within the Biotechnology & Pharmaceuticals area simplifies the management of the company's patent interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELLER, MICHAEL V | 1 | 47.1% | +28.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712962 | COMPOSITION, IN PARTICULAR COSMETIC FORMULATION, COMPRISING A VERBASCOSIDE EXTRACT | MELLER, MICHAEL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712962 | COMPOSITION, IN PARTICULAR COSMETIC FORMULATION, COMPRISING A VERBASCOSIDE EXTRACT | MELLER, MICHAEL V | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712962 | COMPOSITION, IN PARTICULAR COSMETIC FORMULATION, COMPRISING A VERBASCOSIDE EXTRACT | MELLER, MICHAEL V | 1655 | §101§102§103 | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial